Index of drugs

Active immunization against measles, mumps, rubella and chickenpox after finishing 11 months up to 12 years inclusive. In special cases, the use of the vaccine may be considered in infants aged 9-10 months.

1 dose (0.5 ml) contains: not less than 10³ CCID₅₀ measles virus of the Schwarz strain, not less than 10^4,4 CCID₅₀ mumps virus strain RIT 4385 (derived from the strain Jeryl Lynn), not less than 10³ CCID₅₀ rubella virus Wistar RA 27/3 and not less than 10^3,3 PFU of chickenpox virus strain OKA.

Vaccine for simultaneous immunization against measles, mumps, rubella and chickenpox. It contains live attenuated viruses obtained from chicken embryo tissue culture (mumps and measles viruses) and human diploid cells (rubella and varicella virus). In a clinical trial in children aged 11-23. months of age. after two doses of the vaccine, the presence of measles antibodies was found in 99.1%, against mumps 98.8%, anti-rubella in 99.9% and against varicella in 99.2%. The second dose of the vaccine induces higher seroconversion rates and / or levels of measles, mumps and rubella antibodies. Therefore, to avoid infection in the period between doses, it is recommended that the second dose is administered within 3 months after the first dose. The data show the effectiveness and decrease in the number of chickenpox cases "breaking" after the administration of two doses of the vaccine compared to one dose. As with all vaccines, you can not get a protective immune response in all vaccinated people.

Hypersensitivity to active substances, to any of the excipients or to neomycin (neomycin-induced contact dermatitis in contact history is not a contraindication to vaccination). Allergy to chicken eggs. The occurrence of a hypersensitivity reaction after previous administration of measles, mumps, rubella and / or varicella vaccine. Pregnancy. Patients with primary or secondary immunodeficiency. acute severe disease with fever. The presence of a mild infection is not a contraindication to vaccination.

The possibility of proper treatment and medical supervision should always be provided in the event of rare anaphylactic reactions following vaccination. Special care should be taken in patients with a history of febrile seizures, including a family history or in patients with brain injuries; follow closely after vaccination. Vaccination related to vaccination occurs more frequently after the administration of a measles tetravalent vaccine against measles, mumps, rubella and varicella than after simultaneous administration of separate vaccines within 4-12 days after vaccination with the first dose of vaccine. The measles and mumps viruses contained in the vaccine are obtained from chicken embryo tissue production, hence the preparation may contain traces of egg white. Special care should be taken when vaccinating those who have had anaphylactic reaction after ingestion of eggs, ensuring that appropriate measures are available in the event of such a reaction. Salicylates should be avoided for 6 weeks after each administration of the vaccine (the occurrence of Rey's syndrome after the use of salicylates in the course of natural infection with varicella virus has been reported). Vaccinated individuals who develop a rash similar to that occurring in chickenpox should avoid contact with susceptible to chickenpox: pregnant women and people at high risk of severe course of chickenpox (patients with primary and acquired immunodeficiency) until completely disappearance of the rash. Vaccines must not be administered intravascularly or intradermally. After the first dose of live measles, mumps and rubella vaccines, cases of worsening or relapsing thrombocytopenia have been reported in people with this disease; in such cases, the benefit-risk ratio of the vaccine should be carefully assessed.The vaccine has not been studied in people with asymptomatic HIV infection; vaccine use in these patients can be considered with caution if failure to vaccinate poses a greater risk to health. The vaccine contains sorbitol - patients with rare hereditary problems of fructose intolerance should not be vaccinated.

Vaccination during pregnancy is contraindicated. In addition, pregnancy should be avoided within 3 months after vaccination. There are no data on the use of the vaccine during breastfeeding.

Very common: pain and redness at the injection site, fever (in the rectum ≥38st.C-≤ 39.5st.C, under the arm / in the mouth ≥37,5st.C-≤39st.C). Common: rash, swelling at the injection site, fever (in the rectum> 39.5 ° C, underarm / in the mouth> 39 ° C), irritability. Uncommon: generalized enlargement of lymph nodes, rhinitis, diarrhea, vomiting, parotid gland swelling, anorexia, upper respiratory tract infection, lethargy, malaise, fatigue, crying, nervousness, insomnia. Rarely: febrile seizures, cough, bronchitis, otitis media. Following post-marketing, the following reactions have also been reported in relation to measles, mumps, rubella and varicella-antropic disease: thrombocytopenia, platelet purpura, spinal cord inflammation, Guillain Barré syndrome, peripheral neuritis, encephalitis, erythema multiforme, joint pain , arthritis, meningitis, shingles, Kawasaki syndrome, allergic reactions (including anaphylactic and anaphylactoid). In rare cases, a mump-like condition with a shorter incubation period can not be ruled out. Isolated cases of transient, painful swelling of the testis after vaccination with a measles, mumps and rubella combination vaccine have been described.

Subcutaneously, in the region of the deltoid muscle or in the anterolateral upper region of the thigh. Infants and children after finishing 11 months up to 12 years: 2 doses of the vaccine at intervals of 6 weeks - 3 months. If the first dose was administered at the age of 11 months, the second dose should be administered within 3 months. In no case should the interval between doses be less than 4 Alternatively and in accordance with the relevant official recommendations: a single dose of the vaccine may be given to a child who has already received a single dose of another measles, mumps, rubella (MMR) vaccine and / or a single dose of another vaccine against varicella and a single dose of vaccine may precede the administration of a single dose of another vaccine against measles, mumps, rubella (MMR) and / or a single dose of another vaccine against varicella. If the epidemiological situation requires the vaccination of infants below 11 months of age, the first dose of the vaccine may be administered after 9 months of age and the second dose within 3 months of the first dose.